New pharmacotherapeutic approaches for the treatment of peripheral T-cell lymphoma

Today, it is difficult to overestimate the new directions in pharmacotherapy of peripheral T-cell lymphomas (PTCL): immunotherapy, including adoptive, targeted therapy and chemotherapy. However, there are few biomarkers that predict response therapy. A big problem patients with refractory recurrent PTCL who do not respond such or demonstrate adverse events, which makes important personalize search for predictive markers, followed by thorough analytical clinical validation. The literature highlights importance using obtained from whole exome sequencing tumor transcriptome sequencing. Thе review discusses T cell ontogenesis, as well possibilities personalization anticancer drugs azacitidine, duvelisib, romidepsin, bortezomib treatment PTCL.